Cartesian Therapeutics (RNAC) Depreciation and Depletion (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Depreciation and Depletion for 12 consecutive years, with $600000.0 as the latest value for Q1 2026.

  • For Q1 2026, Depreciation and Depletion changed 0.0% year-over-year to $600000.0; the TTM value through Mar 2026 reached $2.4 million, up 50.0%, while the annual FY2025 figure was $2.4 million, 100.0% up from the prior year.
  • Depreciation and Depletion hit $600000.0 in Q1 2026 for Cartesian Therapeutics, roughly flat from $600000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $600000.0 in Q1 2025 and bottomed at $100000.0 in Q1 2022.
  • Average Depreciation and Depletion over 5 years is $329411.8, with a median of $200000.0 recorded in 2022.
  • Year-over-year, Depreciation and Depletion tumbled 50.0% in 2023 and then soared 200.0% in 2024.
  • Cartesian Therapeutics' Depreciation and Depletion stood at $200000.0 in 2022, then changed by 0.0% to $200000.0 in 2023, then surged by 150.0% to $500000.0 in 2024, then increased by 20.0% to $600000.0 in 2025, then changed by 0.0% to $600000.0 in 2026.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $600000.0, $600000.0, and $600000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.